Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione

The purpose of this current opinion article is to illustrate a novel approach to the treatment of acute decompensated heart failure (ADHF) in coronavirus disease 2019 (COVID-19) patients. The approach described herein relies on a reformulation of intravenous nitroglycerin in 5% glutathione, itself n...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaesemeyer, Wayne, Suvorava, Tatsiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982335/
https://www.ncbi.nlm.nih.gov/pubmed/33748918
http://dx.doi.org/10.1007/s40256-021-00474-w
_version_ 1783667698375327744
author Kaesemeyer, Wayne
Suvorava, Tatsiana
author_facet Kaesemeyer, Wayne
Suvorava, Tatsiana
author_sort Kaesemeyer, Wayne
collection PubMed
description The purpose of this current opinion article is to illustrate a novel approach to the treatment of acute decompensated heart failure (ADHF) in coronavirus disease 2019 (COVID-19) patients. The approach described herein relies on a reformulation of intravenous nitroglycerin in 5% glutathione, itself novel, and is felt to have the potential to not only improve the rate of resolution of ADHF, but also reduce the risk of complications of heart failure seen in patients with COVID-19.
format Online
Article
Text
id pubmed-7982335
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79823352021-03-23 Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione Kaesemeyer, Wayne Suvorava, Tatsiana Am J Cardiovasc Drugs Current Opinion The purpose of this current opinion article is to illustrate a novel approach to the treatment of acute decompensated heart failure (ADHF) in coronavirus disease 2019 (COVID-19) patients. The approach described herein relies on a reformulation of intravenous nitroglycerin in 5% glutathione, itself novel, and is felt to have the potential to not only improve the rate of resolution of ADHF, but also reduce the risk of complications of heart failure seen in patients with COVID-19. Springer International Publishing 2021-03-22 2021 /pmc/articles/PMC7982335/ /pubmed/33748918 http://dx.doi.org/10.1007/s40256-021-00474-w Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Current Opinion
Kaesemeyer, Wayne
Suvorava, Tatsiana
Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione
title Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione
title_full Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione
title_fullStr Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione
title_full_unstemmed Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione
title_short Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione
title_sort treating acute decompensated heart failure in patients with covid-19 using intravenous nitroglycerin in 5% glutathione
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982335/
https://www.ncbi.nlm.nih.gov/pubmed/33748918
http://dx.doi.org/10.1007/s40256-021-00474-w
work_keys_str_mv AT kaesemeyerwayne treatingacutedecompensatedheartfailureinpatientswithcovid19usingintravenousnitroglycerinin5glutathione
AT suvoravatatsiana treatingacutedecompensatedheartfailureinpatientswithcovid19usingintravenousnitroglycerinin5glutathione

Ejemplares similares